Zivo Bioscience, INC Form 4 insider transactions

Director Alison A. Cornell reports acquiring 6,273 shares of Zivo Bioscience, Inc. common stock on June 11, 2024.

Christopher D. Maggiore, a director and 10% owner of Zivo Bioscience, Inc., reported the acquisition and disposal of common stock.

Nola E. Masterson, a director of Zivo Bioscience, Inc., filed an amended Form 4 to correct the number of common stock shares beneficially owned, adjusting the total to 122,024 shares after a transaction on June 11, 2024.

Director Christopher D. Maggiore reports acquisition and disposal of Zivo Bioscience stock and cancellation of stock options.

Director Nola E. Masterson reports transactions involving Zivo Bioscience stock, including the acquisition of restricted stock and cancellation of stock options.

Director Alison Cornell reports transactions involving Zivo Bioscience stock and options, including the cancellation of options and receipt of restricted stock.

Keith Marchiando, CFO of Zivo Bioscience, reports the cancellation of existing stock options and the grant of a new replacement option.

John Payne, CEO of Zivo Bioscience, reports the cancellation and grant of stock options in a recent SEC Form 4 filing.

Director Alison Cornell reports acquiring 37,688 shares of Zivo Bioscience and disposing of 83,854 shares on May 31, 2024.